While it is The growing evidence that psychodelical drugs can effectively treat severe mental health conditions, especially in cases where customary treatment has failed, they still come from defects.
Their hallucinogenic effects can be terrifying and overwhelming, and dosage sessions last several hours. Good treatment is largely dependent on the way the individual thinks in the session and the environment in which he receives it. And although it is uncommon, psychhedels can sometimes worsen the existing mental illness.
Mindstate Design Labs is one of a number of modern companies that aim to create safer psychhedels by removing a classic “journey” with them. The company uses artificial intelligence to lend a hand design drugs similar to psychedelic, which cause specific mental states without hallucinations, and its first relationship looks promising.
“We’ve created the least psychedelic psychedelic, which is psychoactive,” says general director of Dillan Dinardo. “It’s quite psychoactive, but there is no hallucinations.”
Established in 2021 and supported by Y Combinator and founders of OpenAI, Neuralink, Instacart, Coinbase and Twitch, Mindstate built a set of AI models that combine biochemical data from various mental drugs to over 70,000 “travel reports” developed from various sources – from official clinical data from test tests and media drugs. social and even Dim.
Platform analysis on how psychhedels have different effects, led to the development of the first drug candidate, MSD-001, a reserved for a 5-me-mipt oral wording, also known as Moxy street. In the results of phase tests and shared with Wired, the drug was secure and well tolerated at five different doses at 47 robust participants. He also created psychoactive effects without causing a monstrous journey, which according to the company is the validation of the AI platform.
While participants reported increased emotions, association thinking, increased imagination and perceptive effects, such as colors that look brighter, did not experience hallucinations, self -integration, and slave, odds.
The company measured the effects of the drug using approved scales used in psychedelic studies and asked the participants subjective questions such as “Are you happy?” And “Are you sad?” Scientists also observed the movement and stability of volunteers and performed brain imaging before, during and after psychoactive effects. By using this brain imaging data, the company was able to determine that the drug produced many of the same brain wave patterns related to psilocybin and other first generation psychedics. “The drug enters the brain and does what we intend,” says Dinardo.
Psychoactive effects began within 30 minutes after the participants took the medicine and the peak intensity takes place about an hour and a half to two hours. The company does not report grave adverse events.
The process that took place in the Center for Human Drug Research in the Netherlands included a mixture of people who in the past tried psychedelics and others who did not do it.
Mindstate’s approach is based on the idea that a psychedelic “journey” may not be necessary for therapeutic benefits. Psychhedels are working on the brain serotonin system by promoting neuroplasticity, which includes the growth of neurons and creating modern connections. Some researchers believe that this ability to stimulate neuroplasticity, and not hallucinogenic effects, is the key to treating mental illness.